Half of people with hepatitis C in the U.S. are aware of their infection, but fewer than 10% have been successfully treated and achieved sustained virological response (SVR), according to a meta-analysis published July 2 in the open-access journal PLoS ONE. Despite these gaps in testing, care, and treatment, hepatitis C accounts for a substantial share of healthcare utilization, especially among baby boomers, a related study found.
In this overview, Paul Sax from Harvard Medical School and Mark Sulkowski from Johns Hopkins School of Medicine discuss selected highlights from the recent Conference on Retroviruses and Opportunistic Infections (CROI 2014), focusing on antiretroviral therapy, HIV cure research, and new treatments for hepatitis C and HIV/HCV coinfection.
More than 100 participants packed the Eureka Valley Recreation Center in San Francisco on May 20 for the latest Real Talk discussion of new HIV prevention strategies including pre-exposure prophylaxis (PrEP) and antiretroviral treatment as prevention.
HIVandHepatitis.com coverage of the 49th European Association for the Study of the Liver's International Liver Congress (EASL 2014) in London, April 9-13, 2014.
Conference highlights include new interferon-free treatments for hepatitis C, hepatitis B and delta, and management of liver disease complications such as cirrhosis and hepatocellular carcioma.